• The Musella Foundation recently awarded Oncoceutics a $25,000 research grant for a project titled “Clinical Evaluation of DRD5 as a Predictive Biomarker of Response to the selective DRD2 antagonist ONC201.” This will fund Oncoceutics’ work evaluating the impact of dopamine receptor expression on the responsiveness of patient tumors to ONC201, with a focus on glioblastoma and other brain cancers.

    The award announcement can be found here.